Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

詳細情報 詳細情報について

• CRID

  1360298759831745536

• DOI

  10.1007/s10637-019-00843-y

• ISSN

  15730646

  01676997

• Web Site

  https://link.springer.com/content/pdf/10.1007/s10637-019-00843-y.pdf

  https://link.springer.com/article/10.1007/s10637-019-00843-y/fulltext.html

• データソース種別

  • Crossref